The Future of B-cell Lymphoma Therapy: the B-cell Receptor and Its Downstream Pathways

Overview

Journal Curr Hematol Malig Rep

Publisher Current Science

Specialties Hematology
Oncology

Date 2012 Jun 13

PMID 22688757

Citations 13

Authors

Vaishalee P Kenkre

Brad S Kahl

Affiliations

Soon will be listed here.

Abstract

It is becoming increasingly apparent that tonic signaling through the B cell receptor provides a growth and survival signal in many types of B cell lymphomas, and that disruption of B cell receptor signaling can be lethal to malignant B cells. Several small molecule tyrosine kinase inhibitors, which block signaling pathways downstream from the B cell receptor, are in active clinical development. Preliminary data suggests impressive activity in relapsed and refractory B cell lymphomas. Among the kinases which have been targeted are Spleen tyrosine kinase (Syk), the Bruton's tyrosine kinase (BTK), and phosphoinositide 3-kinase (PI3K). This article discusses the rationale for targeting these pathways and summarizes the current clinical trial data for agents targeting Syk, BTK, and PI3K.

Citing Articles

Immunomodulatory role of spleen tyrosine kinase in chronic inflammatory and autoimmune diseases.

Zhou Y, Zhang Y, Yu W, Qin Y, He H, Dai F Immun Inflamm Dis. 2023; 11(7):e934.

PMID: 37506139 PMC: 10373573. DOI: 10.1002/iid3.934.

A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies.

Moore D, Thompson D J Adv Pract Oncol. 2021; 12(4):439-447.

PMID: 34123480 PMC: 8163255. DOI: 10.6004/jadpro.2021.12.4.8.

Precursor B-ALL Cell Lines Differentially Respond to SYK Inhibition by Entospletinib.

Sender S, Sekora A, Perez S, Chabanovska O, Becker A, Ngezahayo A Int J Mol Sci. 2021; 22(2).

PMID: 33435587 PMC: 7827334. DOI: 10.3390/ijms22020592.

Management of Older Adults with Mantle Cell Lymphoma.

Romancik J, Cohen J Drugs Aging. 2020; 37(7):469-481.

PMID: 32367497 DOI: 10.1007/s40266-020-00765-y.

Epstein-Barr virus-positive diffuse large B-cell lymphoma features disrupted antigen capture/presentation and hijacked T-cell suppression.

Jiang X, Yu B, Yan W, Lee J, Zhou X, Li X Oncoimmunology. 2020; 9(1):1683346.

PMID: 32002294 PMC: 6959427. DOI: 10.1080/2162402X.2019.1683346.

References

Gururajan M, Jennings C, Bondada S . Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma. J Immunol. 2006; 176(10):5715-9. DOI: 10.4049/jimmunol.176.10.5715. View

Lenz G, Staudt L . Aggressive lymphomas. N Engl J Med. 2010; 362(15):1417-29. PMC: 7316377. DOI: 10.1056/NEJMra0807082. View

Lannutti B, Meadows S, Herman S, Kashishian A, Steiner B, Johnson A . CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2010; 117(2):591-4. PMC: 3694505. DOI: 10.1182/blood-2010-03-275305. View

Davis R, Ngo V, Lenz G, Tolar P, Young R, Romesser P . Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010; 463(7277):88-92. PMC: 2845535. DOI: 10.1038/nature08638. View

Herman S, Gordon A, Hertlein E, Ramanunni A, Zhang X, Jaglowski S . Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011; 117(23):6287-96. PMC: 3122947. DOI: 10.1182/blood-2011-01-328484. View

Irish J, Czerwinski D, Nolan G, Levy R . Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. Blood. 2006; 108(9):3135-42. PMC: 1895530. DOI: 10.1182/blood-2006-02-003921. View

Honigberg L, Smith A, Sirisawad M, Verner E, Loury D, Chang B . The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010; 107(29):13075-80. PMC: 2919935. DOI: 10.1073/pnas.1004594107. View

Chen L, Monti S, Juszczynski P, Daley J, Chen W, Witzig T . SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood. 2007; 111(4):2230-7. PMC: 2234057. DOI: 10.1182/blood-2007-07-100115. View

Satterthwaite A, Witte O . The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective. Immunol Rev. 2000; 175:120-7. View

10.

Monti S, Savage K, Kutok J, Feuerhake F, Kurtin P, Mihm M . Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood. 2004; 105(5):1851-61. DOI: 10.1182/blood-2004-07-2947. View

11.

Chen L, Juszczynski P, Takeyama K, Aguiar R, Shipp M . Protein tyrosine phosphatase receptor-type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling, and cellular proliferation. Blood. 2006; 108(10):3428-33. DOI: 10.1182/blood-2006-03-013821. View

12.

Lam K, Kuhn R, Rajewsky K . In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell. 1997; 90(6):1073-83. DOI: 10.1016/s0092-8674(00)80373-6. View

13.

Kraus M, Alimzhanov M, Rajewsky N, Rajewsky K . Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell. 2004; 117(6):787-800. DOI: 10.1016/j.cell.2004.05.014. View

14.

Rinaldi A, Kwee I, Taborelli M, Largo C, Uccella S, Martin V . Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br J Haematol. 2006; 132(3):303-16. DOI: 10.1111/j.1365-2141.2005.05883.x. View

15.

Friedberg J, Sharman J, Sweetenham J, Johnston P, Vose J, LaCasce A . Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2009; 115(13):2578-85. PMC: 2852362. DOI: 10.1182/blood-2009-08-236471. View